$Pfizer(PFE.US)Pfizer has been showing signs of a strong recovery, climbing toward US$28 as markets rotate into defensive healthcare names. Its improving earnings outlook, recurring cash flow, attractive dividend and pipeline developments continue to support the stock.
As expected preferred to secure the some gain and moving on to the next opportunity during rebound
Watching Pfizer can hold above the support level and break through resistance.
Keeping an eye on earnings recovery, oncology and vaccine pipeline developments, dividend strength and broader defensive sector rotation
Drug pricing pressure, pipeline execution and slower than expected revenue growth could weigh on the stock
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.